Gilead Sciences's Options Frenzy: What You Need to Know

Deep-pocketed investors have adopted a bearish approach towards Gilead Sciences (NASDAQ:GILD), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga

BenzingaJul 11 15:48 ET

J&J to Recognize $1.25B Impact From Yellow Jersey Acquisition

Seeking AlphaJul 11 09:17 ET

Looking Into Gilead Sciences's Recent Short Interest

Gilead Sciences's (NYSE:GILD) short percent of float has fallen 25.98% since its last report. The company recently reported that it has 18.81 million shares sold short, which is 1.51% of all regular

BenzingaJul 10 09:15 ET

Johnson & Johnson Faces MedTech Challenges But Is 'On Track' to Meet 2024 Guidance, Goldman Says

U.S. pharma giant Johnson & Johnson (NYSE:JNJ) will report its second-quarter 2024 earnings on Wednesday, July 17.As per data from Benzinga Pro, analysts estimate sales of $22.29 billion and

BenzingaJul 9 14:59 ET · Earnings Preview

Citi Research's AI Hedge Stocks - Part II

Seeking AlphaJul 9 13:22 ET

Citi Research's AI Hedge Stocks - Part I

Seeking AlphaJul 9 13:20 ET